A 58-year-old man with type 2 diabetes mellitus and hypertension presents for routine follow-up. His lipid profile shows: Total cholesterol 280 mg/dL, LDL-C 180 mg/dL, HDL-C 35 mg/dL, triglycerides 320 mg/dL. He is already on atorvastatin 40 mg daily but remains at high cardiovascular risk. His liver function tests and creatine kinase are normal. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Context This 58-year-old diabetic, hypertensive patient has mixed dyslipidemia: LDL-C 180 mg/dL, HDL-C 35 mg/dL, and TG 320 mg/dL despite atorvastatin 40 mg daily. He is at high cardiovascular risk with normal LFTs and CK. The primary therapeutic goal per current guidelines is aggressive LDL-C lowering. ## Why Increasing Atorvastatin to 80 mg Is Correct **Key Point:** Per ACC/AHA 2018/2019 and ESC/EAS 2019 guidelines, the **primary target in high-risk patients is LDL-C reduction**. In a patient already on moderate-intensity statin (atorvastatin 40 mg) with LDL-C still markedly elevated at 180 mg/dL, the **first step is to intensify statin therapy** to high-intensity (atorvastatin 80 mg or rosuvastatin 20–40 mg). **High-Yield:** Atorvastatin 80 mg is a high-intensity statin that reduces LDL-C by ≥50% from baseline. This is the most evidence-based next step before adding adjunct agents. The patient's normal LFTs and CK make dose escalation safe and appropriate. **Clinical Pearl:** Triglycerides of 320 mg/dL are elevated but do not reach the threshold (≥500 mg/dL) where fibrate therapy is urgently indicated to prevent pancreatitis. At TG 200–499 mg/dL, LDL-C reduction remains the primary goal; statin intensification also provides modest TG reduction (10–20%). ## Mechanism of High-Intensity Statin Therapy 1. HMG-CoA reductase inhibition → reduced hepatic cholesterol synthesis 2. Upregulation of LDL receptors → increased LDL-C clearance 3. Modest reduction in VLDL/TG (10–20%) 4. Atorvastatin 80 mg reduces LDL-C by ~50–55% vs. ~40–45% with 40 mg ## Why Other Options Are Suboptimal **Fenofibrate (Option C):** Fibrates are indicated when TG ≥500 mg/dL (pancreatitis risk) or as add-on after LDL-C goal is achieved. Adding fenofibrate before maximizing statin dose is not guideline-concordant when LDL-C remains markedly elevated. The statin + fenofibrate combination also carries myopathy risk. **Ezetimibe (Option D):** Ezetimibe is appropriate as add-on therapy *after* high-intensity statin fails to achieve LDL-C goal — not before maximizing statin dose. **Switch to rosuvastatin 20 mg (Option B):** Rosuvastatin 20 mg is also high-intensity, but switching rather than intensifying the current statin is a less direct step. Atorvastatin 80 mg is the simpler, guideline-preferred escalation from atorvastatin 40 mg. ## Guideline Alignment **High-Yield:** ACC/AHA 2018 Cholesterol Guidelines recommend a stepwise approach: 1. **Step 1:** Maximize statin intensity (high-intensity statin) 2. **Step 2:** Add ezetimibe if LDL-C goal not met on high-intensity statin 3. **Step 3:** Add PCSK9 inhibitor if still not at goal Fibrates are reserved for TG ≥500 mg/dL or as adjuncts after LDL-C targets are achieved. **Reference:** Grundy SM et al. 2018 AHA/ACC Guideline on Management of Blood Cholesterol. *JACC* 2019; KD Tripathi, Essentials of Medical Pharmacology, 8th ed., Chapter on Hypolipidemic Drugs.